Sosei Co. Ltd, a leading Japanese biopharmaceutical company with operations in Japan and the UK, announces that it has agreed terms with Arakis and its shareholders to combine its business with Arakis Limited, a private UK-based biopharmaceutical company, bringing together two highly successful product discovery and development companies. The enlarged group will have a broad mid- to late-stage clinical and pre-clinical pipeline, products with near term revenue generation potential, complementary product discovery capabilities and strengths in Europe and Asia.
Fifth Secondaries Market Report also reveals that 97% of secondaries investors are participating in GP-leds
French sponsor beats Ardian and Antin in race for a majority stake in French veterinary chain
Fund is headed by Kirsten Connell and Maria Rotilu and has extended its hard cap to GBP 15m following a first close
BGF exits energy markets consultancy following minority stake investment in 2017